Event Description
Employers continue to fight the good fight in managing the high cost of specialty drugs and cell and gene therapies, while at the same time ensuring they are providing high-quality health care and benefits to their employees and families. PBM legislation has stalled, transparency legislation is not working in the ways intended and despite our efforts, employer costs are still too high. Intermediary waste continues to be prevalent, which increases costs without providing added value. We need resolution, including strategies and ideas for the future! Attend this important full-day program to learn what you as an employer can do.
According to MBGH’s 2023 Employer Health Benefits Survey, 81% of employers feel that market-based AND government reform is needed to make the pharmacy drug market competitive.
This program is available both in-person and virtually.